Item 7.01 Regulation FD Disclosure.
On January 14, 2021, NextCure, Inc. ("NextCure") announced that Dr. Han Myint,
MD, FACP, has been appointed to serve as NextCure's chief medical officer. In
this role, Dr. Myint will oversee the clinical development of key products in
NextCure's product pipeline.
Before joining NextCure, Dr. Myint served as chief medical officer at NexImmune
Inc., a clinical-stage biotechnology company developing unique approaches to T
cell immunotherapies. Prior to NexImmune, he was Vice President of Global
Medical Affairs and the Myeloid Diseases Lead at Celgene (a Bristol Myers Squibb
Company). His work in myeloid diseases at Celgene contributed to a number of
Food and Drug Administration approvals, successful product launches and
high-impact publications. Prior to joining the biopharmaceutical industry, Dr.
Myint practiced medicine, specializing in hematological oncology, and conducted
clinical and laboratory research at multiple academic institutions in the United
Kingdom and the United States, including Rush University Medical Center in
Chicago and the University of Colorado, Denver. As Professor of Medicine, Dr.
Mynt built a Foundation for the Accreditation of Cellular Therapy-accredited and
Center of Excellence-designated stem cell transplant program at the University
of Colorado, Denver. Dr. Myint graduated from the Institute of Medicine in
Yangon, Myanmar with a MBBS degree and subsequently emigrated to the United
Kingdom for postgraduate training in internal medicine, followed by training in
hematology.
A copy of NextCure's press release announcing Dr. Myint's appointment is
attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated
herein by reference.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Description
99.1 Press release of NextCure, Inc. dated January 14, 2021.
© Edgar Online, source Glimpses
NEXTCURE, INC. 
